TIGIT is a hot topic in immuno-oncology at the moment, with drug candidates attracting some sizeable deals of late involving GlaxoSmithKline/iTeos and Bristol-Myers Squibb/Agenus. At the moment ...

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 31-03-2025, ...